- Home
- NSTS vs APLT Comparison
NSTS vs APLT Comparison
Compare NSTS & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSTS
- APLT
- Stock Information
- Founded
- NSTS 1921
- APLT 2016
- Country
- NSTS United States
- APLT United States
- Employees
- NSTS N/A
- APLT N/A
- Industry
- NSTS Savings Institutions
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- NSTS Finance
- APLT Health Care
- Exchange
- NSTS Nasdaq
- APLT Nasdaq
- Market Cap
- NSTS 63.0M
- APLT 69.0M
- IPO Year
- NSTS N/A
- APLT 2019
- Fundamental
- Price
- NSTS $11.74
- APLT $0.44
- Analyst Decision
- NSTS
- APLT Buy
- Analyst Count
- NSTS 0
- APLT 6
- Target Price
- NSTS N/A
- APLT $6.10
- AVG Volume (30 Days)
- NSTS 1.8K
- APLT 896.6K
- Earning Date
- NSTS 08-14-2025
- APLT 11-06-2025
- Dividend Yield
- NSTS N/A
- APLT N/A
- EPS Growth
- NSTS N/A
- APLT N/A
- EPS
- NSTS N/A
- APLT N/A
- Revenue
- NSTS $9,435,000.00
- APLT $121,000.00
- Revenue This Year
- NSTS N/A
- APLT N/A
- Revenue Next Year
- NSTS N/A
- APLT $5,931.24
- P/E Ratio
- NSTS N/A
- APLT N/A
- Revenue Growth
- NSTS 69.39
- APLT N/A
- 52 Week Low
- NSTS $9.37
- APLT $0.30
- 52 Week High
- NSTS $13.32
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- NSTS 32.60
- APLT 42.40
- Support Level
- NSTS $11.90
- APLT $0.46
- Resistance Level
- NSTS $11.99
- APLT $0.53
- Average True Range (ATR)
- NSTS 0.06
- APLT 0.03
- MACD
- NSTS -0.01
- APLT -0.01
- Stochastic Oscillator
- NSTS 0.00
- APLT 0.00
About NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.